Acute Renal Failure under Dasatinib Therapy

被引：26

作者：

Ozkurt, Sultan ^{[1
]}

Temiz, Gokhan ^{[1
]}

Acikalin, Mustafa Fuat ^{[2
]}

Soydan, Mehmet ^{[1
]}

机构：

[1] Eskisehir Osmangazi Univ, Fac Med, Dept Nephrol, TR-26140 Meselik, Eskisehir, Turkey

[2] Eskisehir Osmangazi Univ, Fac Med, Dept Pathol, TR-26140 Meselik, Eskisehir, Turkey

来源：

RENAL FAILURE | 2010年 / 32卷 / 01期

关键词：

acute renal failure; chronic myeloid leukemia; tyrosine kinase inhibitors; dasatinib; IMATINIB MESYLATE TREATMENT; TYROSINE KINASE; INHIBITOR; SECONDARY; LEUKEMIA; AMN107;

D O I：

10.3109/08860220903391226

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Dasatinib is a second-generation tyrosine kinase inhibitor that is approved for the treatment of imatinib-resistant or imatinib-intolerant chronic myeloid leukemia. It has a 325 times stronger in vitro activity against to native BCR-ABL when comparing with imatinib. Little is known about the effects of dasatinib on renal function. A literature review revealed only one case with imatinib-resistant chronic myeloid leukemia that developed renal failure after being placed on dasatinib therapy. Here we report a patient with imatinib-resistant chronic myeloid leukemia who developed gastroenteritis and acute renal failure after a short time from the initiation of dasatinib therapy. After dasatinib interruption, these side effects resolved completely in days. In summary, dasatinib is a potent drug in the treatment of chronic myeloid leukemia, but close clinical monitoring and the timely interruption of the therapy in patients who developed acute renal failure are warranted.

引用

页码：147 / 149

页数：3

共 12 条

[1] Metabolism and disposition of dasatinib after oral administration to humans [J].

Christopher, Lisa J. ;

Cui, Donghui ;

Wu, Chiyuan ;

Luo, Roger ;

Manning, James A. ;

Bonacorsi, Samuel J. ;

Lago, Michael ;

Allentoff, Alban ;

Lee, Francis Y. F. ;

McCann, Betty ;

Galbraith, Susan ;

Reitberg, Donald P. ;

He, Kan ;

Barros, Anthony, Jr. ;

Blackwood-Chirchir, Anne ;

Humphreys, W. Griffith ;

Iyer, Ramaswamy A. .

DRUG METABOLISM AND DISPOSITION, 2008, 36 (07) :1357-1364

[2] Acute renal failure secondary to imatinib mesylate treatment in prostate cancer [J].

Foringer, JR ;

Verani, RR ;

Tjia, VM ;

Finkel, KW ;

Samuels, JA ;

Guntupalli, JS .

ANNALS OF PHARMACOTHERAPY, 2005, 39 (12) :2136-2138

[3] Partial Fanconi syndrome induced by imatinib therapy: A novel cause of urinary phosphate loss [J].

Francois, Helene ;

Coppo, Paul ;

Hayman, Jean-Philippe ;

Fouqueray, Bruno ;

Mougenot, Beatrice ;

Ronco, Pierre .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2008, 51 (02) :298-301

[4] Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia [J].

Holstein, Sarah A. ;

Stokes, John B. ;

Hohl, Raymond J. .

LEUKEMIA RESEARCH, 2009, 33 (02) :344-347

[5] Dasatinib Treatment for Philadelphia Chromosome-positive Leukemias Practical Considerations [J].

Khoury, Hanna Jean ;

Guilhot, Francois ;

Hughes, Timothy P. ;

Kim, Dong-Wook ;

Cortes, Jorge E. .

CANCER, 2009, 115 (07) :1381-1394

[6] Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571 [J].

Kitiyakara, C ;

Atichartakarn, V .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 (04) :685-687

[7] In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants [J].

O'Hare, T ;

Walters, DK ;

Stoffregen, EP ;

Jia, TP ;

Manley, PW ;

Mestan, J ;

Cowan-Jacob, SW ;

Lee, FY ;

Heinrich, MC ;

Deininger, MWN ;

Druker, BJ .

CANCER RESEARCH, 2005, 65 (11) :4500-4505

[8] Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia [J].

Pou, M ;

Saval, N ;

Vera, M ;

Saurina, A ;

Solé, M ;

Cervantes, F ;

Botey, A .

LEUKEMIA & LYMPHOMA, 2003, 44 (07) :1239-1241

[9] Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure [J].

Sonmez, M. ;

Cobanoglu, U. ;

Ovali, E. ;

Omay, S. B. .

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2008, 33 (03) :329-330

[10] Dasatinib: A tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia [J].

Steinberg, Michael .

CLINICAL THERAPEUTICS, 2007, 29 (11) :2289-2308

← 1 2 →